Findings

What do systematic reviews say?

2,079 questions · 2,112 findings · 171 reviews · Eyes and Vision

Sort:Best matchNewestHighest certainty Download CSV

No studies found 587 · 27.8%GRADE not reported 95 · 4.5%Very low 446 · 21.1%Low 557 · 26.4%Moderate 361 · 17.1%High 66 · 3.1%

Intervention not reported

Frequency and nature of adverse effects · Participants with a diagnosis of JIA and uveitis who are aged 2 to 18 years old

1 finding from 1 review

Tumor necrosis factor (TNF) inhibitors for juvenile idiopathic arthritis‐associated uveitis 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 134 participants
Low

Topical antibiotics vs another topical antibiotic or placebo

Risk of any ocular infection within 1 month following corneal abrasion · children and adults with corneal abrasion

1 finding from 1 review

Antibiotic prophylaxis for corneal abrasion 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Very low

Topical antibiotics vs another topical antibiotic or placebo

Time to clinical cure · children and adults with corneal abrasion

1 finding from 1 review

Antibiotic prophylaxis for corneal abrasion 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Very low

Topical antibiotics vs another topical antibiotic or placebo

Change in pain intensity from baseline to 1 month · children and adults with corneal abrasion

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotic prophylaxis for corneal abrasion 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Topical antibiotics vs another topical antibiotic or placebo

Recurrent corneal erosion within 1 year · children and adults with corneal abrasion

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotic prophylaxis for corneal abrasion 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Topical antibiotics vs another topical antibiotic or placebo

Visual acuity · children and adults with corneal abrasion

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotic prophylaxis for corneal abrasion 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Topical antibiotics vs another topical antibiotic or placebo

Quality of life at 1 month · children and adults with corneal abrasion

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotic prophylaxis for corneal abrasion 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Topical antibiotics vs another topical antibiotic or placebo

Adverse effects · children and adults with corneal abrasion

1 finding from 1 review

Antibiotic prophylaxis for corneal abrasion 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Low

Non‐biologic disease‐modifying antirheumatic drugs (DMARDs) vs steroids

Proportion of participants achieving control of inflammation (higher number of events is better) · NIIPPU

It is very uncertain whether non‐biologic disease‐modifying antirheumatic drugs (DMARDs) changes proportion of participants achieving control of inflammation (higher… compared with steroid (very low certainty).

1 finding from 1 review

Non‐biologic, steroid‐sparing therapies for non‐infectious intermediate, posterior, and panuveitis in adults 2022 · Cochrane Headline outcomes only
RR 2.81 [1.1, 7.17]
1 study · 41 participants
Very low

Methotrexate vs mycophenolate

Proportion of participants with confirmed macular edema (lower number of events is better) · NIIPPU

It is very uncertain whether methotrexate changes proportion of participants with confirmed macular edema (lower… compared with mycophenolate (very low certainty).

1 finding from 1 review

Non‐biologic, steroid‐sparing therapies for non‐infectious intermediate, posterior, and panuveitis in adults 2022 · Cochrane Headline outcomes only
RR 0.49 [0.19, 1.3]
1 study · 35 participants
Very low

Methotrexate vs mycophenolate

Proportion of participants achieving steroid‐sparing control (higher number of events is better) · NIIPPU

Methotrexate probably leads to higher proportion of participants achieving steroid‐sparing control§… compared with mycophenolate (moderate certainty).

1 finding from 1 review

Non‐biologic, steroid‐sparing therapies for non‐infectious intermediate, posterior, and panuveitis in adults 2022 · Cochrane Headline outcomes only
RR 1.23 [1.01, 1.5]
2 studies · 261 participants
Moderate

Methotrexate vs mycophenolate

Proportion of participants experiencing complications or requiring cessation of medication (lower number of events is better) · NIIPPU

Methotrexate showed no clear difference in proportion of participants experiencing complications or requiring… compared with mycophenolate (low certainty).

1 finding from 1 review

Non‐biologic, steroid‐sparing therapies for non‐infectious intermediate, posterior, and panuveitis in adults 2022 · Cochrane Headline outcomes only
RR 0.99 [0.43, 2.27]
2 studies · 296 participants
Low

Steroids with or without azathioprine vs cyclosporine A

Proportion of participants achieving control of inflammation (higher number of events is better) · NIIPPU

It is very uncertain whether steroids with or without azathioprine changes proportion of participants achieving control of inflammation (higher… compared with cyclosporine A (very low certainty).

1 finding from 1 review

Non‐biologic, steroid‐sparing therapies for non‐infectious intermediate, posterior, and panuveitis in adults 2022 · Cochrane Headline outcomes only
RR 0.84 [0.7, 1.02]
2 studies · 112 participants
Very low

Steroids with or without azathioprine vs cyclosporine A

Change in BCVA (lower logMAR indicate better vision) · NIIPPU

1 finding from 1 review

Non‐biologic, steroid‐sparing therapies for non‐infectious intermediate, posterior, and panuveitis in adults 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 91 participants
Very low

Steroids with or without azathioprine vs cyclosporine A

Proportion of participants achieving a 2‐line improvement in visual acuity (Snellen chart) (higher scores indicate better vision) · NIIPPU

The review found no eligible studies for this question.

1 finding from 1 review

Non‐biologic, steroid‐sparing therapies for non‐infectious intermediate, posterior, and panuveitis in adults 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Steroids with or without azathioprine vs cyclosporine A

Proportion of participants with confirmed macular edema (lower number of events is better) · NIIPPU

The review found no eligible studies for this question.

1 finding from 1 review

Non‐biologic, steroid‐sparing therapies for non‐infectious intermediate, posterior, and panuveitis in adults 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Steroids with or without azathioprine vs cyclosporine A

Proportion of participants achieving steroid‐sparing control (higher number of events is better) · NIIPPU

It is very uncertain whether steroids with or without azathioprine changes proportion of participants achieving steroid‐sparing control (higher… compared with cyclosporine A (very low certainty).

1 finding from 1 review

Non‐biologic, steroid‐sparing therapies for non‐infectious intermediate, posterior, and panuveitis in adults 2022 · Cochrane Headline outcomes only
RR 0.64 [0.33, 1.25]
1 study · 21 participants
Very low

Steroids with or without azathioprine vs cyclosporine A

Proportion of participants experiencing complications or requiring cessation of medication (lower number of events is better) · NIIPPU

It is very uncertain whether steroids with or without azathioprine changes proportion of participants experiencing complications or requiring… compared with cyclosporine A (very low certainty).

1 finding from 1 review

Non‐biologic, steroid‐sparing therapies for non‐infectious intermediate, posterior, and panuveitis in adults 2022 · Cochrane Headline outcomes only
RR 0.85 [0.21, 3.45]
2 studies · 91 participants
Very low

Non‐biologic disease‐modifying antirheumatic drugs (DMARDs) vs steroids

Change in BCVA (lower logMAR indicate better vision) · NIIPPU

1 finding from 1 review

Non‐biologic, steroid‐sparing therapies for non‐infectious intermediate, posterior, and panuveitis in adults 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 82 participants
Very low

Non‐biologic disease‐modifying antirheumatic drugs (DMARDs) vs steroids

Proportion of participants achieving a 2‐line improvement in visual acuity (Snellen chart) (higher scores indicate better vision) · NIIPPU

The review found no eligible studies for this question.

1 finding from 1 review

Non‐biologic, steroid‐sparing therapies for non‐infectious intermediate, posterior, and panuveitis in adults 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found